ZSAN - Zosano Pharma Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.28
-0.40 (-8.55%)
As of 12:58PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.68
Open4.68
Bid4.26 x 900
Ask4.28 x 900
Day's Range4.08 - 4.68
52 Week Range3.61 - 27.40
Volume737,475
Avg. Volume431,753
Market Cap51.244M
Beta2.07
PE Ratio (TTM)N/A
EPS (TTM)-16.82
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Trade prices are not sourced from all markets
  • Zosano Pharma’s Positive Non-Clinical Trial Results
    Market Realist22 hours ago

    Zosano Pharma’s Positive Non-Clinical Trial Results

    Today, Zosano Pharma is trading at a stock price of $4.38, which represents ~5.92% growth from its closing price of $4.14 yesterday. $4.14 represented ~15% growth from the stock’s 52-week low of $3.61 on February 13. Zosano Pharma hit a 52-week high of $27.8 on July 18, 2017.

  • GlobeNewswireyesterday

    Zosano Announces Positive Data from a Nonclinical Evaluation of Pharmacokinetics and Skin Tolerability Study for ADAM™ Technology for the Delivery of Zolmitriptan

    Peer-reviewed article published in Journal of Pharmaceutical Science evaluates skin tolerability and bioavailability of ADAM’ s intracutaneous zolmitriptan delivery. FREMONT, Calif., July 17, 2018-- Zosano ...

  • ACCESSWIRE16 days ago

    Initiating Free Research Reports on ZIOPHARM Oncology and Three Other Biotech Equities

    Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...

  • Zosano Pharma (ZSAN) Stock Can Reach $19 in the Next 12 Months, Says BTIG
    SmarterAnalyst20 days ago

    Zosano Pharma (ZSAN) Stock Can Reach $19 in the Next 12 Months, Says BTIG

    Yes, you're reading this right. BTIG analyst Robert Hazlett is expecting Zosano Pharma (NASDAQ:ZSAN) shares to reach $19.00 in the next 12 months, which implies an upside of 400% from current levels. In a very upbeat and promising report, Hazlett explains why he is initiating coverage on ZSAN with a Buy rating: "We believe M&A potential exists with Zosano [...] Since Zosano is effectively a one product company with a modest infrastructure, there is a reasonable chance that a larger industry suitor could emerge and take over the company’s operations. The analyst continued, "We assess the total value of M207 at $16.21 per ZSAN share, assuming Zosano continues to operate independently.

  • GlobeNewswire21 days ago

    Zosano to Present Additional Analyses from the ZOTRIP Pivotal Study on Pain Relief and Recurrence at the 2018 American Headache Society (AHS) Meeting

    Zosano Pharma, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid systemic absorption using a novel and proprietary technology called Adhesive Dermally-Applied Microarray (“ADAM™”) with the potential to transform patient lives and advance patient care, announced additional analyses from the Phase 2/3 clinical study on pain relief by time and recurrence of migraine in subjects with pain relief at two hours will be presented at the American Headache Society Meeting. A poster and oral presentation on receptor and binding kinetics will also be presented during the 60th Annual Scientific Meeting to be held on June 28 – July 1, 2018 in San Francisco, CA.

  • GlobeNewswire28 days ago

    Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAM™) Technology for the Delivery of Zolmitriptan in Migraine in Journal of Pharmaceutics

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announces the recent publication of a peer-reviewed paper regarding ADAM technology for the delivery of zolmitriptan in the Journal of Pharmaceutics. “Our in vitro study presents guidance on use of the appropriate skin model to assess intracutaneous delivery of compounds using the ADAM platform.  This particular study, assessing the intracutaneous delivery of zolmitriptan, is the first of its kind and we are excited to present the results,” said Hayley Lewis, senior vice president, operations at Zosano Pharma.

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in ANSYS, Pearson, Qualys, H. B. Fuller, Cabot Microelectronics, and Zosano Pharma — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, May 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ANSYS, ...

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks

    Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.

  • GlobeNewswire2 months ago

    Zosano Announces Publication of Most Bothersome Symptom Data from the ZOTRIP Pivotal Study in Headache: The Journal of Head and Face Pain

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that Headache, the Journal of Head and Face Pain, has published the post-hoc analysis on the use of most bothersome symptom (MBS) as a co-primary endpoint from the Company’s ZOTRIP pivotal study. Headache published the paper titled “Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial”. The paper analyzes the positive MBS results from Zosano’s ZOTRIP pivotal study, a multi-center, double-blind, placebo-controlled trial demonstrating the efficacy and safety of M207, Zosano’s novel proprietary formulation of zolmitriptan using its ADAM technology.  The ZOTRIP pivotal study, evaluating ADAM zolmitriptan for the acute treatment of migraine, was one of the first large studies to incorporate MBS freedom and pain freedom as co-primary endpoints, per recently issued guidance by the US Food and Drug Administration.  MBS freedom at two hours was observed in 68% of M207 3.8 mg subjects as compared to 43% of placebo subjects (P

  • GlobeNewswire2 months ago

    Zosano Appoints Steven A. Elms to Board of Directors

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that Steven A. Elms, Managing Partner at Aisling Capital, has been appointed to the Company’s Board of Directors. "On behalf of our entire Board, I am pleased to welcome Steven as a member of our Board of Directors," commented John Walker, Chief Executive Officer and Chairman of the Board.

  • GlobeNewswire2 months ago

    Zosano Pharma Reports First Quarter 2018 Financial Results and Operational Update

    Completion of follow on offering netting $45.7 million Issuance of new US patent Long-term safety study now has 250 subjects enrolled. FREMONT, Calif., May 15, 2018-- Zosano Pharma Corporation a clinical-stage ...

  • GlobeNewswire2 months ago

    Zosano Reaches Another Enrollment Milestone in M207-ADAM Long-term Safety Study

    Zosano Pharma Corp. (ZSAN) (“Zosano” or the “Company”), a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that the 250th subject has enrolled and received M207 in the M207-ADAM study (the “Study”), a long-term safety study for the acute treatment of migraines.

  • GlobeNewswire2 months ago

    Zosano Pharma to Host Conference Call on First Quarter 2018 Financial Results and Provide Operational Update

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that it will host a conference call and webcast to be held on Tuesday, May 15, 2018 at 4:30PM ET. The Company will announce its financial results for this period in a press release to be issued prior to the call. To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at http://ir.zosanopharma.com/events.cfm.

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tesla Inc (NASDAQ: TSLA ) stock rebounded modestly ...

  • ACCESSWIRE4 months ago

    Wired News – Zosano Reports Enrollment Milestone in its M207-ADAM Study

    Stock Monitor: Albireo Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Zosano Pharma Corp. (NASDAQ: ZSAN ) ("Zosano"). ...

  • Should You Buy Zosano Pharma Corporation (NASDAQ:ZSAN) Now?
    Simply Wall St.4 months ago

    Should You Buy Zosano Pharma Corporation (NASDAQ:ZSAN) Now?

    Zosano Pharma Corporation (NASDAQ:ZSAN), a medical equipment company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. As aRead More...

  • Benzinga4 months ago

    The Market In 5 Minutes: Trump And Kim Jung Un, Toys 'R' Us Liquidation, Zosano's Move, Big Payrolls Beat

    IN THE NEWS Zosano Pharma Corp (NASDAQ: ZSAN ) stock rocketed higher by more than 50 percent Thursday and is now up 295 percent in the past week after coming alive following a new patent last Friday: Link ...